Amgen Inc. $AMGN Shares Acquired by Czech National Bank

Czech National Bank lifted its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 4.8% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 153,622 shares of the medical research company’s stock after purchasing an additional 6,969 shares during the period. Czech National Bank’s holdings in Amgen were worth $55,630,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Vanguard Group Inc. raised its holdings in shares of Amgen by 1.8% during the fourth quarter. Vanguard Group Inc. now owns 54,838,826 shares of the medical research company’s stock valued at $17,949,296,000 after acquiring an additional 961,975 shares during the last quarter. State Street Corp increased its position in shares of Amgen by 4.4% during the fourth quarter. State Street Corp now owns 30,591,403 shares of the medical research company’s stock worth $10,012,872,000 after purchasing an additional 1,287,310 shares in the last quarter. Capital World Investors increased its position in shares of Amgen by 22.9% during the fourth quarter. Capital World Investors now owns 23,097,711 shares of the medical research company’s stock worth $7,560,249,000 after purchasing an additional 4,302,237 shares in the last quarter. Geode Capital Management LLC raised its stake in Amgen by 7.8% in the 4th quarter. Geode Capital Management LLC now owns 14,303,294 shares of the medical research company’s stock valued at $4,665,822,000 after purchasing an additional 1,035,779 shares during the last quarter. Finally, Norges Bank purchased a new position in Amgen in the 4th quarter valued at $2,164,162,000. 76.50% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

AMGN has been the topic of several recent research reports. Sanford C. Bernstein lifted their target price on shares of Amgen from $335.00 to $345.00 and gave the stock a “market perform” rating in a research note on Thursday. Argus decreased their price target on shares of Amgen from $400.00 to $375.00 and set a “buy” rating on the stock in a research note on Wednesday, May 20th. Bank of America boosted their price target on shares of Amgen from $312.00 to $317.00 and gave the stock an “underperform” rating in a research report on Wednesday. BMO Capital Markets upped their price objective on shares of Amgen from $400.00 to $450.00 and gave the company an “outperform” rating in a research note on Wednesday. Finally, Scotiabank increased their price objective on shares of Amgen from $385.00 to $450.00 and gave the company an “outperform” rating in a report on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, fifteen have issued a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $367.93.

Amgen Stock Down 0.7%

NASDAQ AMGN opened at $404.85 on Friday. Amgen Inc. has a 52 week low of $269.77 and a 52 week high of $418.40. The company has a quick ratio of 1.01, a current ratio of 1.37 and a debt-to-equity ratio of 4.44. The business’s fifty day simple moving average is $361.29 and its 200-day simple moving average is $355.86. The firm has a market cap of $218.50 billion, a PE ratio of 25.16, a P/E/G ratio of 4.10 and a beta of 0.41.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, August 4th. The medical research company reported $6.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.62 by $0.67. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The firm had revenue of $10.05 billion during the quarter, compared to analyst estimates of $9.43 billion. During the same quarter in the prior year, the firm posted $6.02 earnings per share. Amgen’s quarterly revenue was up 9.5% on a year-over-year basis. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. As a group, equities analysts anticipate that Amgen Inc. will post 22.47 earnings per share for the current year.

Amgen Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, September 11th. Shareholders of record on Friday, August 21st will be issued a $2.52 dividend. This represents a $10.08 annualized dividend and a yield of 2.5%. The ex-dividend date is Friday, August 21st. Amgen’s payout ratio is presently 70.15%.

Amgen News Roundup

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen reported second-quarter revenue of $10.05 billion, up approximately 9.5% year over year, while adjusted EPS of $6.29 exceeded the roughly $5.62 analyst consensus. Growth across cardiovascular, bone-health, and rare-disease medicines helped offset pressure from older products facing biosimilar competition. Amgen second-quarter sales rise 9%, profit tops Street view
• Positive Sentiment: Management raised its 2026 outlook, with adjusted EPS guidance of $22.30 to $23.50 and revenue guidance of approximately $38.2 billion to $39.4 billion. The update reflects momentum across Amgen’s portfolio and continued progress in its late-stage pipeline. AMGN Beats on Q2 Earnings, Lifts Outlook Despite Legacy Drug Pressure
• Positive Sentiment: Several firms raised their targets following the results. UBS lifted its target to $440 and TD Cowen to $452, while BMO, Oppenheimer, and Scotiabank set targets near $450 or higher; UBS and TD Cowen maintained bullish ratings. Amgen Price Target Raised to $440 at UBS
• Neutral Sentiment: Analyst sentiment remains divided. Citi maintained a Hold rating, while UBS retained Buy; other firms raised targets but kept Hold, Equal Weight, or Underperform ratings, suggesting some analysts believe the upgraded outlook is already reflected in the valuation. Citi Keeps Their Hold Rating on Amgen
• Negative Sentiment: Amgen abandoned an obesity-drug candidate, while pressure from biosimilars and weaker performance in some legacy franchises remains a headwind. Questions surrounding Tavneos clinical data add regulatory and reputational uncertainty. Amgen Stock Climbs as Drug Growth Outruns Obesity Setback
• Negative Sentiment: A reported patient-data breach has prompted a law-firm investigation into potential privacy claims, creating additional legal, operational, and reputational risk for Amgen. Amgen Data Breach Class Action Investigation

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.